Director/PDMR Shareholding

June 28, 2021
var w=window;if(w.performance||w.mozPerformance||w.msPerformance||w.webkitPerformance){var d=document;AKSB=w.AKSB||{},AKSB.q=AKSB.q||[],AKSB.mark=AKSB.mark||function(e,_){AKSB.q.push(["mark",e,_||(new Date).getTime()])},AKSB.measure=AKSB.measure||function(e,_,t){AKSB.q.push(["measure",e,_,t||(new Date).getTime()])},AKSB.done=AKSB.done||function(e){AKSB.q.push(["done",e])},AKSB.mark("firstbyte",(new Date).getTime()),AKSB.prof={custid:"793678",ustr:"",originlat:"0",clientrtt:"2",ghostip:"23.222.16.133",ipv6:false,pct:"10",clientip:"52.207.178.49",requestid:"19dfc910",region:"40057",protocol:"",blver:14,akM:"dsca",akN:"ae",akTT:"O",akTX:"1",akTI:"19dfc910",ai:"501146",ra:"false",pmgn:"",pmgi:"",pmp:"",qc:""},function(e){var _=d.createElement("script");_.async="async",_.src=e;var t=d.getElementsByTagName("script"),t=t[t.length-1];t.parentNode.insertBefore(_,t)}(("https:"===d.location.protocol?"https:":"http:")+"//ds-aksb-a.akamaihd.net/aksb.min.js")}
RNS Number : 3397D
Renalytix PLC
28 June 2021
 

Renalytix plc  

("Renalytix" or the "Company")

 

Director/PDMR Dealing

 

The Company had been informed today that Christopher Mills, a non-executive director and interim Chairman, completed the sale of 6,100 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of £11.25 per share.

 

Following completion of the sale, Christopher Mills is interested in 9,174,401 Ordinary Shares representing 12.71% of the issued share capital of the Company as enlarged by the recent option exercise.

 

For further information, please contact: 

 

Renalytix plc  

www.renalytix.com 

James McCullough, CEO  

Via Walbrook PR  



Stifel (Nominated Adviser, Joint Broker) 

Tel: 020 7710 7600 

Alex PriceNicholas Moore  




Investec Bank plc (Joint Broker) 

Tel: 020 7597 4000 

Gary Clarence / Daniel Adams 




Walbrook PR Limited 

Tel: 020 7933 8780 or renalytix@walbrookpr.com 

Paul McManus / Lianne Cawthorne 

Mob: 07980 541 893 / 07584 391 303 

 

About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.1 Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year, kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

1 https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

 

About KidneyIntelX

KidneyIntelX, is a first-of-kind, bioprognosticTM platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

 

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name 

 

 

 

Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Christopher Mills, the issuer's interim chairman, is Chief Executive Officer of Harwood

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name 

 

 

Renalytix AI plc

b)

 

LEI

 

 

213800NTOH3FK3WER551

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of  £0.0025 each



Identification code

GB00BYWL4Y04

 

 


b)

 

Nature of the transaction

 

 

Sale of shares

c)

 

Price(s) and volume(s)

 

 

 

 


 

Price(s)

Volume(s)

 


 

£11.25

6,100

 


 

 

 

 

d)

 

Aggregated information




- Aggregated volume

6,100



- Price

£68,625.00



e)

 

Date of the transaction

 

 

25 June 2021

f)

 

Place of the transaction

 

 

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAEKPALKFEFA